Transient receptor potential vanilloid 1 (TRPV1) (TRPV1)

Transient receptor potential vanilloid 1 (TRPV1) is a non-selective cation channel primarily expressed in sensory neurons, where it acts as a polymodal detector of noxious stimuli including high temperature, acidic pH, and vanilloid compounds [UniProt P51788]. In the context of pharmacology, TRPV1 is a critical mediator of the analgesic effects of acetaminophen (paracetamol). Acetaminophen is metabolized in the brain by fatty acid amide hydrolase (FAAH) into N-arachidonoylaminophenol (AM404), which subsequently activates TRPV1 receptors in the central nervous system to facilitate antinociception [PMID: 16135770]. Beyond its role in acute pain, TRPV1 is heavily implicated in chronic inflammatory and neuropathic pain states, making it a major target for analgesic development [PMID: 9349813]. Structurally, TRPV1 is a tetrameric protein with each subunit containing six transmembrane segments and a pore-forming loop. It is also found in non-neuronal tissues such as the bladder and skin, where it contributes to local inflammatory responses and epithelial barrier function. The channel's sensitivity is modulated by various intracellular signaling pathways, including phosphorylation by protein kinase C (PKC), which lowers the threshold for activation during inflammation. Therapeutic strategies include the use of potent agonists to induce long-term desensitization of sensory fibers or the development of antagonists to block channel activation, though the latter has been complicated by side effects like hyperthermia [PMID: 23533133].

Other names

Capsaicin receptorVanilloid receptor 1VR1OTRPC1Transient receptor potential vanilloid 1 via AM404 metabolite

Acetaminophen is metabolized by fatty acid amide hydrolase (FAAH) into N-arachidonoylaminophenol (AM404), which acts as an agonist of TRPV1 in the central nervous system, leading to antinociception through channel desensitization and modulation of descending pain pathways [PMID: 16135770].